Impella RP for Patients with Acute Right Ventricular Failure and Cardiogenic Shock: A Subanalysis from the IMP-IT Registry

The use of percutaneous right ventricular assist devices (pRVADs) to support patients with right ventricular (RV)-predominant cardiogenic shock (CS) refractory to optimal medical therapy is increasing progressively, and the Impella RP is the first FDA-approved pRVAD in such a clinical scenario. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Botti, Giulia, Gramegna, Mario, Burzotta, Francesco, Masiero, Giulia, Briguori, Carlo, Trani, Carlo, Napodano, Massimo, Scandroglio, Anna Mara, Montorfano, Matteo, Tarantini, Giuseppe, Chieffo, Alaide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506315/
https://www.ncbi.nlm.nih.gov/pubmed/36143266
http://dx.doi.org/10.3390/jpm12091481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506315/
https://www.ncbi.nlm.nih.gov/pubmed/36143266
http://dx.doi.org/10.3390/jpm12091481

Ejemplares similares